Physician profile
James Stanford
NPI 1033220512
$2,622.51
in general payments reported to CMS, 2019-2025
31 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $318 · 2021: $550 · 2022: $418 · 2023: $529 · 2024: $420 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,216.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $684.92 | 2021-2025 | Qulipta, Vraylar |
| Lilly USA, LLC | $222.91 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $219.48 | 2019-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $213.55 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $171.33 | 2019-2025 | Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $129.88 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.03 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $89.60 | 2020-2021 | |
| Amgen INC. | $86.53 | 2020-2023 | Otezla, Repatha |
| Idorsia Pharmaceuticals US INC | $77.68 | 2022-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $70.50 | 2021-2022 | |
| Abbott Laboratories | $67.65 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Eisai INC. | $55.00 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.19 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $36.57 | 2024 | Voquezna |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $36.53 | 2022-2023 | Adlarity |
| Allergan, INC. | $30.04 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.97 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $25.42 | 2023 | Dificid |
| Mylan Specialty L.P. | $25.34 | 2024 | Yupelri |
| Olympus America INC. | $24.85 | 2020 | |
| Medtronic USA, INC. | $23.00 | 2020 | |
| Genzyme Corporation | $22.95 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $21.70 | 2023 | Nuedexta |
| Bayer Healthcare Pharmaceuticals INC. | $21.18 | 2022 | |
| Corcept Therapeutics | $20.52 | 2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $19.09 | 2022 | |
| Glaxosmithkline, LLC. | $16.09 | 2021 | |
| Biogen, INC. | $15.91 | 2021 | |
| Adlon Therapeutics L.P. | $13.11 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Stanford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.